本次合作将Mirxes的突破性miRNA及多组学技术、核心产品(GASTROClear及 LUNGClear)及其日益成 熟的临床管线(涵盖结直肠癌、肝癌、乳癌的成熟临床管线及CADENCE多癌种检测)与Apollo丰富的临 床专业知识、全国医院网络及社区医疗服务的提供能力结合，以实现宏伟的愿景：及早检测癌症、于可 治愈时介入及改变数百万患者的治疗结果。 智通财经APP讯，MIRXES-B(02629)发布公告，本公司已与Apollo Health and Lifestyle Limited(AHLL， 为 Apollo Hospitals Enterprise Limited(Apollo)的全资附属公司)订立谅解备忘录以寻求进行战略合作，从 而于印度及邻近国家共同开发及商业化先进的癌症早期检测解决方案。待达成协定目标及获各自董事会 批准后，预期将会于印度创立一家合营公司，根据本公司及Apollo 将注入的知识产权、临床管线、研 发、临床试验基础设施及商业渠道，其股权价值将不少于5000万美元。 作为亚洲首屈一指的医疗服务提供者，Apollo及AHLL于南亚及中东以其先进医疗服务而广受认可，并 致力于提升其 ...

Group 1 - MIRXES-B has signed a memorandum of understanding with Apollo Health and Lifestyle Limited to seek strategic cooperation for the development and commercialization of advanced cancer early detection solutions in India and neighboring countries [1] - The anticipated joint venture in India will have a minimum equity value of $50 million, based on the intellectual property, clinical pipeline, research and clinical trial facilities, and commercial channels contributed by both companies [1] - Apollo is recognized as a leading healthcare provider in Asia and aims to enhance its global leadership position in preventive oncology and disease management [1] Group 2 - The collaboration will combine Mirxes' breakthrough miRNA and multi-omics technologies, core products (GASTROClear and LUNGClear), and its mature clinical pipeline with Apollo's extensive clinical expertise and nationwide hospital network [2] - The goal of the partnership is to scale the commercialization and market adoption of these solutions, thereby expanding the coverage of early disease screening in the region [2] - The board believes that this strategic cooperation with Apollo represents a significant synergistic opportunity that aligns with the long-term strategic goals of the company [2]

本公告乃由Mirxes Holding Company Limited（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，旨在知會本公司股東及潛在投資者有關本集團的最新業務 發展。 諒解備忘錄 本公司董事（「董事」）會（「董事會」）宣佈，本公司已與Apollo Health and Lifestyle Limited（「AHLL」，為Apollo Hospitals Enterprise Limited（「Apollo」）的全資附屬公 司）訂立諒解備忘錄（「諒解備忘錄」）以尋求進行戰略合作，從而於印度及鄰近 國家共同開發及商業化先進的癌症早期檢測解決方案。待達成協定目標及獲 各自董事會批准後，預期將會於印度創立一家合營公司，根據本公司及Apollo 將注入的知識產權、臨床管線、研發、臨床試驗基礎設施及商業渠道，其股權 價值將不少於50百萬美元。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 Mirxes Holding Company Limite ...

Core Viewpoint - Mirxes Holding Company Limited has successfully completed a new share placement, raising approximately HKD 711 million, reflecting strong investor confidence in its technology and business prospects, marking a significant step towards market expansion in cancer early screening [1][6]. Group 1: Fundraising and Strategic Focus - The recent share placement was priced at HKD 32.5 per share, a 40% premium over its IPO price of HKD 23.30 [1]. - Approximately 30% of the raised funds will be allocated for investment and acquisition activities, 25% for research and development, 20% for expanding into emerging markets like India, and 25% for general operational expenses [2]. Group 2: Product Pipeline and Development - As of June 30, 2025, the company has one core product (GASTROClear), two commercialized products (LUNGClear and Fortitude), and six candidates in preclinical stages [3]. - GASTROClear, a blood-based miRNA test for gastric cancer screening, has received regulatory approval in both Singapore and China, marking significant milestones in its commercialization [3]. Group 3: Collaborations and Market Strategy - Mirxes has signed a memorandum of understanding with Crystal Technology to develop an AI-enabled integrated diagnosis and treatment platform, enhancing its capabilities in early detection and intervention [4]. - The company is implementing a dual strategy of "professional medical + innovative channels" to increase market penetration and public awareness, collaborating with top hospitals and health institutions in China [5]. Group 4: Industry Context and Competitive Position - The cancer early screening sector is gaining traction, highlighted by Abbott's USD 21 billion acquisition of Exact Sciences, indicating the strategic value recognized by major medical companies [6]. - Mirxes, as one of the earliest companies focused on miRNA cancer screening in Asia, has established a comprehensive capability from biomarker discovery to commercialization, positioning itself as a leader in the rapidly growing industry [6].

Core Insights - The company has established a strategic partnership with N Health and Bangkok Dusit Medical Services to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step forward in early cancer detection and patient outcomes in the region [1][2] Group 1: Strategic Partnership and Market Growth - The partnership aims to penetrate the rapidly growing health check market in Thailand, which is expected to reach approximately $500 million by 2030, with a compound annual growth rate (CAGR) of 9.2% starting from 2025 [1] - The specialized health check segment is the fastest-growing part of the market, indicating strong demand for advanced and targeted screening solutions [1] Group 2: Cancer Screening Solutions - The partnership will leverage the company's cutting-edge miRNA technology and innovative screening solutions, such as GASTROClear for gastric cancer and LUNGClear for lung cancer, to improve cancer treatment standards in the region [2] - Nearly 60 hospitals within the N Health network will adopt the cancer screening tests, supporting broader access to early disease detection services across Thailand and Southeast Asia [2] Group 3: Home Testing Kits Launch - The company announced the launch of new home screening test kits, HELICORapid for H. pylori detection and FITRapid for fecal occult blood detection, in Thailand, following approvals from the Thai FDA [3] - These home test kits are the first of their kind in the Thai market, designed to integrate sample collection and testing into a single, user-friendly device, significantly reducing contamination and user error risks [3][4] Group 4: Accessibility and Consumer Engagement - The home test kits will be distributed through modern trade channels and pharmacies across Thailand, catering to evolving consumer healthcare behaviors and the increasing demand for preventive, self-diagnostic solutions [4] - The launch emphasizes the company's mission to democratize early detection, empowering individuals with practical tools to manage their health and support the healthcare system through early intervention and increased disease awareness [4]

Core Viewpoint - Mirxes has signed a memorandum of understanding with Watson Bio to collaborate in molecular diagnostics and vaccine development, aiming to expand into ASEAN and global markets [1] Group 1: Company Developments - Mirxes' stock rose nearly 8% in early trading, currently up 2.48% at HKD 53.8, with a trading volume of HKD 18.2942 million [1] - The partnership with Watson Bio signifies a strategic collaboration between a leading precision diagnostics company and a top vaccine developer, establishing a solid foundation for an RNA-based preventive and precision medical platform [1] Group 2: Product Approval and Market Impact - In October, Mirxes' core product GASTROClear received approval from the National Medical Products Administration (NMPA) in China, becoming the world's first and only approved molecular diagnostic IVD product for gastric cancer screening [1] - This milestone represents a commercial breakthrough for the company, transitioning from "0 to 1," and is expected to lead to a revaluation of the company's worth [1] - The approval allows Mirxes to enter the vast gastric cancer screening market in China, serving as a significant catalyst for short-term performance [1]

Core Insights - Mirxes-B (02629) experienced a nearly 8% increase in early trading, currently up 2.48% at 53.8 HKD with a trading volume of 18.29 million HKD [1] Company Developments - On November 18, Mirxes announced a formal memorandum of understanding with Watson Bio (300142.SZ) to collaborate in the fields of molecular diagnostics and vaccine development, aiming to expand in the ASEAN and global markets [1] - This partnership signifies a strategic alignment between a leading precision diagnostics company and a top vaccine development firm, laying a solid foundation for a prevention and precision medicine platform centered around RNA [1] Product Milestones - In October, Mirxes' core product GASTROClear received approval from the National Medical Products Administration (NMPA) in China, becoming the world's first and currently the only approved molecular diagnostic IVD product for gastric cancer screening [1] - This milestone represents a significant commercial breakthrough for the company, transitioning from "0 to 1," and introduces a new valuation logic for the firm [1] - The approval allows the company to officially enter the vast gastric cancer screening market in China, serving as a crucial catalyst for short-term performance [1]

Core Viewpoint - MIRXES-B (02629) has been officially included in the Hang Seng Composite Index and Hong Kong Stock Connect as of September 8, 2025, which is expected to attract significant southbound capital attention and allocation, providing additional upward momentum for the company's stock price [1] Group 1: Market Position and Product Advantage - The company is a global pioneer in gastric cancer early screening, possessing first-mover advantages and technological barriers [1] - The core product GASTROClear is the world's first and only approved molecular diagnostic IVD product for gastric cancer screening, having achieved commercialization in markets such as Singapore and Thailand, and received "breakthrough medical device" designation from the US FDA [1] - The company has over ten years of R&D accumulation in miRNA technology and a strong patent portfolio, including 27 approved patents and 63 pending patent applications, positioning it favorably in the non-invasive cancer early screening market, particularly in Asia where gastric cancer is prevalent [1] Group 2: Revenue Growth and Financial Performance - The company expects revenues for 2025, 2026, and 2027 to be $0.27 billion, $0.41 billion, and $0.75 billion, respectively, with year-on-year growth rates of 30.84%, 55.14%, and 81.32% [1] - In the first half of 2025, the revenue from the "early detection and precision multi-omics" division increased by 50% year-on-year to $10.5 million, driven primarily by GASTROClear and LUNGClear [1] Group 3: Product Pipeline and Future Growth - The company has a clear product pipeline supported by its mature miRNART-qPCR technology platform, with ongoing development of screening products for colorectal cancer (CRC-1), liver cancer (LV-1), and breast cancer (BC-1), as well as a multi-cancer screening project (CADENCE) [2] - LUNGClear has been commercialized as an LDT service in Southeast Asia and Japan, while CRC-1 is expected to complete prototype design and initiate commercialization in Southeast Asia by the second half of 2025 [2] - The pipeline for liver cancer (LV-1) and breast cancer (BC-1) is in early development stages, and the CADENCE project has initiated large-scale clinical research, providing long-term growth potential for the company [2] Group 4: Integrated Industry Capability - The company has established an integrated platform covering R&D, production, and commercialization, creating high barriers and cost advantages [3] - With two cGMP-compliant production facilities in Singapore and China, the company has an annual total capacity of approximately 590,000 tests, ensuring product quality and stable supply while effectively controlling costs [3] - The gross margin for the first half of 2025 increased by 18.8 percentage points to 67.8%, laying a solid foundation for future market competition and profit release [3]

Core Viewpoint - MIRXES-B (02629) has been officially included in the Hang Seng Composite Index and Hong Kong Stock Connect as of September 8, 2025, which is expected to attract significant southbound capital attention and allocation, providing additional upward momentum for the company's stock price [1] Group 1: Market Position and Growth Potential - The company is a global pioneer in gastric cancer early screening, possessing first-mover advantages and technological barriers [1] - The core product, GASTROClear, is the world's first and only approved molecular diagnostic IVD product for gastric cancer screening, commercialized in markets such as Singapore and Thailand, and recognized as a "breakthrough medical device" by the US FDA [1] - The company has a strong patent portfolio with over ten years of R&D in miRNA technology, including 27 approved patents and 63 pending applications, positioning it favorably in the non-invasive cancer early screening market, especially in Asia where gastric cancer is prevalent [1] - Revenue projections for 2025-2027 are $0.27 billion, $0.41 billion, and $0.75 billion, reflecting year-on-year growth rates of 30.84%, 55.14%, and 81.32% respectively [1] Group 2: Product Pipeline and Technological Development - The company has established a clear product pipeline leveraging its mature miRNART-qPCR technology platform, with ongoing development of screening products for colorectal cancer (CRC-1), liver cancer (LV-1), and breast cancer (BC-1), as well as a multi-cancer screening project (CADENCE) [2] - LUNGClear (lung cancer) has been commercialized as an LDT service in Southeast Asia and Japan, while CRC-1 is expected to complete prototype design by the second half of 2025 and initiate commercialization in Southeast Asia [2] - The platform's scalability allows for the replication of GASTROClear's success, potentially shortening R&D cycles and continuously launching new products [2] Group 3: Integrated Industry Capabilities - The company has built an integrated platform covering R&D, production, and commercialization, creating high barriers and cost advantages [3] - With two cGMP-compliant production facilities in Singapore and China, the company has an annual testing capacity of approximately 590,000 tests, ensuring product quality and stable supply while effectively controlling costs [3] - The gross margin for the first half of 2025 increased by 18.8 percentage points to 67.8%, providing a solid foundation for future market competition and profit release [3]

Core Insights - MIRXES-B's core product GASTROClear has received approval from the National Medical Products Administration of China for use as a non-invasive gastric cancer screening IVD product, marking a significant milestone in the company's journey from research and development to commercialization [1] - GASTROClear is the first blood test approved for gastric cancer screening in China, utilizing a microRNA-based method to assess gastric cancer risk by detecting 12 gastric cancer-related miRNA biomarkers [1] Group 1 - GASTROClear is designated for screening high-risk adults aged 45-74 as defined by the "Guidelines for Screening and Early Diagnosis and Treatment of Gastric Cancer in China (2024 Edition)," potentially covering over 500 million individuals [2] - The product will be implemented in both public and private medical institutions in China as an IVD testing project, significantly expanding the company's business space in the gastric cancer screening market [2] Group 2 - The company plans to continue increasing its commercialization efforts in China, including expanding the sales team and upgrading local production capabilities [2] - There will be a focus on strengthening business development and collaboration in mainland China to promote broader adoption of the product [2]